Inkef’s Post

🚨 𝗡𝗲𝘄 𝗜𝗻𝘃𝗲𝘀𝘁𝗺𝗲𝗻𝘁 𝗢𝗽𝗽𝗼𝗿𝘁𝘂𝗻𝗶𝘁𝘆: ARJUNA Therapeutics Today marks the launch of the investment round for the spin-off from the University of Santiago de Compostela, which is focused on developing cancer treatments with no effective therapeutic options. You may recall this project from its previous #investmentround with Capital Cell. Since then, ARJUNA Therapeutics has achieved significant milestones, enhancing the large-scale production of Ag5, its flagship drug. Ag5 introduces a novel mechanism of action that targets multiple tumor sites simultaneously. The #treatment has shown positive results in nearly 50% of cancer types, including challenging cases like pancreatic cancer and glioblastoma. Additionally, its efficacy is enhanced with other treatments, such as radiotherapy. 💡The investments made until 12/4 will have a 10% discount. 📲 Access the ARJUNA Therapeutics investment page: https://shorturl.at/jBFAn --- 𝘍𝘰𝘭𝘭𝘰𝘸 Capital Cell 𝘢𝘯𝘥 𝘥𝘪𝘴𝘤𝘰𝘷𝘦𝘳 𝘴𝘰𝘮𝘦 𝘰𝘧 𝘵𝘩𝘦 𝘣𝘦𝘴𝘵 𝘪𝘯𝘷𝘦𝘴𝘵𝘮𝘦𝘯𝘵 𝘰𝘱𝘱𝘰𝘳𝘵𝘶𝘯𝘪𝘵𝘪𝘦𝘴 𝘪𝘯 𝘣𝘪𝘰𝘵𝘦𝘤𝘩, 𝘩𝘦𝘢𝘭𝘵𝘩𝘵𝘦𝘤𝘩, 𝘢𝘯𝘥 𝘭𝘪𝘧𝘦 𝘴𝘤𝘪𝘦𝘯𝘤𝘦 𝘢𝘤𝘳𝘰𝘴𝘴 𝘌𝘶𝘳𝘰𝘱𝘦. 🧪🇪🇺

Prepare to be inspired! Speaker Spotlight: Dr. Jagath Reddy Junutula We are ecstatic to announce that Dr. Jagath Reddy Junutula, a titan in oncology drug discovery and development, will be sharing his wealth of knowledge at our Drug Discovery & Development Workshop! With an illustrious career exceeding three decades, Dr. Junutula has been at the forefront of innovation, notably contributing to significant breakthroughs in cancer therapy. His pioneering efforts in THIOMAB technology have significantly advanced the field of antibody-drug conjugates, paving the way for groundbreaking advancements in cancer therapy. At our workshop, Dr. Junutula will dive deep into the essentials of drug discovery, shedding light on target identification & validation, and the crucial role of small molecules. Furthermore, he's set to provide an in-depth exploration of the promising domain of designer drugs — a session you surely wouldn't want to miss. This is your chance to absorb knowledge from a visionary in the field! Register now to attend Dr. Junutula's sessions and unlock insights that could redefine your perspective on drug discovery and development. Make sure to secure your place and elevate your expertise in the evolving landscape of biotechnology! Don't miss out! Register here: https://lnkd.in/ekGgYQkZ #DrugDiscovery #PrecisionMedicine #FABAInnovationSummit2024 #Biotech #PharmaIndustry

We are thrilled to share the exciting news of CyGenica, a Venture Center incubatee, securing an investment of $450,000 from Golden Sparrow. Under the leadership of Dr. Sanghamitra, CyGenica has developed a safe, effective, and affordable drug delivery platform - GEENIE - that holds great promise for targeted intracellular drug delivery for patients fighting Glioblastoma Multiforme (GBM), others cancers and rare diseases. Congratulations to Dr. Nusrat Sanghamitra PhD, SK Fazlul Krishnan and the team at CyGenica on this significant milestone! We’re glad to be part of your journey and look forward to seeing your continued progress in advancing targeted intracellular therapeutics. #drugdelivery #braincancer #cancer #rarediseases #Glioblastoma #startupfunding #fundingalert #investmentnews

Latest DON Monte Carlo news. Ivo Timmermans will be a guest speaker at Meet the DONs Virtual Event returns on the 30th of May. Pleco Therapeutics BV is to demonstrate the market value and therapeutic potential of our proprietary Plecoid™️ products through an initial focus on treatments for orphan cancers. Thereafter we can expand our scalable product platform for the treatment of other cancers as well as neurodegenerative disorders where aberrant metal patterns have been shown to play a role. Our current pre-clinical development programs focus on the development of treatments for Acute Myeloid Leukaemia (AML), a relatively rare blood cancer, and Small-Cell Lung Cancer (SCLC), an aggressive subtype of lung cancer. Both diseases carry a poor prognosis. This unique online event brings together exclusive opportunities and sophisticated investors. Are you a sophisticated investor or company leader keen to cooperate with Pleco Therapeutics, if so please register to attend via this link - https://lnkd.in/eAq8KZFT DON the most multifaceted HNW & UHNW Business network in Monaco. #event #business #networking #healthcare #biotech #therapeutics

Latest DON Monte Carlo news. Ivo Timmermans will be a guest speaker at Meet the DONs Virtual Event returns on the 30th of May 2024. Pleco Therapeutics BV mission is to demonstrate the market value and therapeutic potential of our proprietary Plecoid™️ products through an initial focus on treatments for orphan cancers. Thereafter we can expand our scalable product platform for the treatment of other cancers as well as neurodegenerative disorders where aberrant metal patterns have been shown to play a role. Our current pre-clinical development programs focus on the development of treatments for Acute Myeloid Leukaemia (AML), a relatively rare blood cancer, and Small-Cell Lung Cancer (SCLC), an aggressive subtype of lung cancer. Both diseases carry a poor prognosis. This unique online event brings together exclusive opportunities and sophisticated investors. Are you a sophisticated investor or company leader keen to cooperate with Pleco Therapeutics, if so please register to attend via this link - https://lnkd.in/eAq8KZFT DON the most multifaceted HNW & UHNW Business network in Monaco. #investors #ceos #biotechnology

🔬 Breaking Biotech News: FogPharma Raises $145M Series E for Revolutionary Cancer Drug Development TL;DR: • Secured $145M led by Nextech Invest • Advancing FOG-001 through Phase 1/2 trials • Targeting beta-catenin protein for tumor inhibition • Notable backing from RA Capital, Arch Venture Partners, GV Former J&J executive Mathai Mammen leads the charge as CEO, joined by veteran biotech investor Alexis Borisy on the board. The funding arrives amid a shifting biotech landscape where companies are strategically choosing to remain private longer. What sets this apart: FogPharma's innovative "Helicon" polypeptide drugs are tackling previously undruggable targets, particularly in colorectal cancer. The pipeline extends to prostate, ovarian, and pancreatic cancer programs. Key Quote: "This financing enables us to accelerate FOG-001's clinical development while strengthening our discovery efforts against other compelling intracellular targets." - Mathai Mammen, CEO 💭 What are your thoughts on the evolving private funding landscape in biotech? Share your insights below. #BiotechNews #CancerResearch #VentureFunding #Innovation #Healthcare #intelligencesimplified #pharma #biotech #biodatastudio

𝗡𝗮𝗻𝗼𝗯𝗼𝘁𝘀 𝗵𝗮𝘀 𝗮𝗹𝗿𝗲𝗮𝗱𝘆 𝘀𝘂𝗿𝗽𝗮𝘀𝘀𝗲𝗱 𝗶𝘁𝘀 𝘁𝗮𝗿𝗴𝗲𝘁 𝗼𝗻 𝗖𝗮𝗽𝗶𝘁𝗮𝗹 𝗖𝗲𝗹𝗹. 🚀 Nanobots Therapeutics, a Spanish biotech company developing self-propelled nanorobots capable of navigating over bodily fluids and penetrating solid tumour barriers, has exceeded its €1.5M target thanks to 218 #investors. 👏🏼 You can still invest in this groundbreaking #project, which focuses its first application on treating bladder cancer. One of the main challenges in this type of cancer is delivering chemotherapy effectively to the tumor. Tests conducted so far show that #nanobots are highly effective at enhancing the efficiency of antitumor treatments, and the company is gearing up to move this first product into clinical trials. From Capital Cell, we’d like to congratulate Samuel Sánchez and the entire Nanobots Therapeutics team. 🥳 💡 Only 10 days remaining until this investment round closes! 📲 Access 𝗡𝗮𝗻𝗼𝗯𝗼𝘁𝘀' investment page: https://bit.ly/3ZmZd12 --- 𝘍𝘰𝘭𝘭𝘰𝘸 Capital Cell 𝘢𝘯𝘥 𝘥𝘪𝘴𝘤𝘰𝘷𝘦𝘳 𝘴𝘰𝘮𝘦 𝘰𝘧 𝘵𝘩𝘦 𝘣𝘦𝘴𝘵 𝘪𝘯𝘷𝘦𝘴𝘵𝘮𝘦𝘯𝘵 𝘰𝘱𝘱𝘰𝘳𝘵𝘶𝘯𝘪𝘵𝘪𝘦𝘴 𝘪𝘯 𝘣𝘪𝘰𝘵𝘦𝘤𝘩, 𝘩𝘦𝘢𝘭𝘵𝘩𝘵𝘦𝘤𝘩, 𝘢𝘯𝘥 𝘭𝘪𝘧𝘦 𝘴𝘤𝘪𝘦𝘯𝘤𝘦 𝘢𝘤𝘳𝘰𝘴𝘴 𝘌𝘶𝘳𝘰𝘱𝘦. 🧪🇪🇺

At RIANA Therapeutics, we try to make what was considered impossible possible by targeting transcription factors and developing novel treatments for blood cancer patients. 🌟 We made huge progress in just one year, from starting a company to advancing the first compounds to a hit-to-lead stage. 🌟 Now, we are looking for partners to bring these compounds closer to patients - drop me a line if you might be such a partner! #biotech #investmentopportunity #startup

🎥 Video Interview : Cizzle Biotechnology Expanding into USA and Transforming Cancer Screening 🚨 Cizzle Biotechnology’s Executive Chairman, Dr. Allan Syms, recently sat down for an exclusive interview with DirectorsTalk Interviews to discuss a game-changing moment for the company—expanding into the US market through a new licensing and partnership agreement for its groundbreaking CIZ1B biomarker. In this insightful conversation, Dr. Syms dives into Cizzle’s innovative approach to early lung cancer detection, the importance of their strategic partnerships (like BIO and Moffitt Cancer Centre), and how their cutting-edge technology is poised to revolutionize cancer screening globally. 🌍 With lung cancer being one of the leading causes of cancer deaths worldwide, early detection is critical. Cizzle Biotechnology’s work with the CIZ1B biomarker is leading the charge, offering a more accurate and cost-effective solution compared to traditional methods like low-dose CT scans. This interview not only highlights the company’s scientific advancements but also explores their ambitious global expansion plans, particularly in North America. 📈 👉 Watch the full video now to learn how Cizzle is making waves in the fight against lung cancer: https://lnkd.in/djcncH-F #CizzleBiotechnology #CancerScreening #HealthcareInnovation #LungCancer #EarlyDetection #Biomarkers #HealthcareTransformation #BioTech